Nvidia, Eli Lilly to spend $1 billion over five years
Digest more
Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...
Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...
Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.
The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...
France's Finance Ministry said on Monday it had received no formal request for investment approval regarding French biotech ...
Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...
Barchart on MSN
What to Expect From Eli Lilly’s Q4 2025 Earnings Report
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback